News

Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity
Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...
Novo Nordisk A/S: ECO 2025 - Novo Nordisk semaglutide data shows new health benefits across serious chronic diseases
Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...
NBC Los Angeles13d
Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
"We are pleased the court has rejected the compounders' attempts to undermine FDA's data-based decision that the shortage" of ...
Novo Nordisk wins case to kick knockoff Ozempic off the market, but it may not last
Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.
Novo Nordisk Predicts Strong Second Half
The immediate market reaction to Novo Nordisk's earnings report was a positive one. As of 7 a.m. EDT, a few hours after the earnings release, shares of the drugmaker were up by about 5%. In short, the ...
Novo Nordisk Q1 2025: One Of The Best Deals You Can Get Right Now
Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...
Pharmabiz3d
US FDA accepts Novo Nordisk’s NDA submission for oral semaglutide 25 mg for treatment of obesity
Plainsboro, New Jersey Monday, May 5, 2025, 14:00 Hrs [IST] ...